Primary 3-Month Outcomes of a Double-Blind Randomized Prospective Study (The QUEST Study) Assessing Effectiveness and Safety of Novel High-Frequency Electric Nerve Block System for Treatment of Post-Amputation Pain
DOI: https://doi.org/10.2147/jpr.s463727
IF: 2.8319
2024-06-07
Journal of Pain Research
Abstract:Leonardo Kapural, 1 Jim Melton, 2 Billy Kim, 3 Priyesh Mehta, 4 Abindra Sigdel, 5 Alexander Bautista, 6 Erika A Petersen, 7 Konstantin V Slavin, 8, 9 John Eidt, 10 Jiang Wu, 11 Said Elshihabi, 12 Jason Matthew Schwalb, 13 H Edward Garrett Jr, 14 Elias Veizi, 15 Giancarlo Barolat, 16 Ravi R Rajani, 17 Peter C Rhee, 18 Maged Guirguis, 19 Nagy Mekhail 20 1 Carolinas Pain Institute and Center for Clinical Research, Winston-Salem, NC, USA; 2 Department of Vascular Surgery, Cardiovascular Health Clinic, Oklahoma City, OK, USA; 3 Department of Vascular Surgery, The Surgical Clinic, Nashville, TN, USA; 4 Department of Pain Medicine, Meta Medical Research Institute, Dayton, OH, USA; 5 Department of Surgery, University of Louisville, Louisville, KY, USA; 6 Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY, USA; 7 Department of Neurosurgery, University of Arkansas, Little Rock, AR, USA; 8 Department of Neurosurgery, University of Illinois at Chicago, Chicago, IL, USA; 9 Department of Neurology, Jesse Brown VA Medical Center, Chicago, IL, USA; 10 Department of Vascular Surgery, Baylor Scott and White Heart and Vascular Hospital Dallas, Dallas, TX, USA; 11 Department of Anesthesiology & Pain Medicine, University of Washington Medical Center, Seattle, WA, USA; 12 Department of Neurosurgery, Legacy Brain & Spine Surgical Center, Atlanta, GA, USA; 13 Department of Neurosurgery, Henry Ford Medical Group, Detroit, MI, USA; 14 Department of Vascular Surgery, University of Tennessee-Memphis, Memphis, TN, USA; 15 Department of Pain Medicine, VA Northeast OH Healthcare System, Cleveland, OH, USA; 16 Department of Neurosurgery, Barolat Neuroscience, Presbyterian/St Luke's Medical Center, Denver, CO, USA; 17 Department of Vascular Surgery, Emory University and Grady Memorial Hospital, Atlanta, GA, USA; 18 Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA; 19 Department of Interventional Pain Management, Ochsner Health System, New Orleans, LA, USA; 20 Department of Pain Management, Cleveland Clinic, Cleveland, OH, USA Correspondence: Leonardo Kapural, Carolinas Pain Institute and Center for Clinical Research, 145 Kimel Park Dr &num330, Winston-Salem, NC, 27103, USA, Email Purpose: This multicenter, randomized, double-blinded, active sham-controlled pivotal study was designed to assess the efficacy and safety of high-frequency nerve block treatment for chronic post-amputation and phantom limb pain. Patients and Methods: QUEST enrolled 180 unilateral lower-limb amputees with severe post-amputation pain, 170 of whom were implanted with the Altius device, were randomized 1:1 to active-sham or treatment groups and reached the primary endpoint. Responders were those subjects who received ≥ 50% pain relief 30 min after treatment in ≥ 50% of their self-initiated treatment sessions within the 3-month randomized period. Differences between the active treatment and sham control groups as well as numerous secondary outcomes were determined. Results: At 30-min, (primary outcome), 24.7% of the treatment group were responders compared to 7.1% of the control group (p=0.002). At 120-minutes following treatment, responder rates were 46.8% in the Treatment group and 22.2% in the Control group (p=0.001). Improvement in Brief Pain Inventory interference score of 2.3 ± 0.29 was significantly greater in treatment group than the 1.3 ± 0.26-point change in the Control group (p = 0.01). Opioid usage, although not significantly different, trended towards a greater reduction in the treatment group than in the control group. The incidence of adverse events did not differ significantly between the treatment and control groups. Conclusion: The primary outcomes of the study were met, and the majority of Treatment patients experienced a substantial improvement in PAP (regardless of meeting the study definition of a responder). The significant in PAP was associated with significantly improved QOL metrics, and a trend towards reduced opioid utilization compared to Control. These data indicate that Altius treatment represents a significant therapeutic advancement for lower-limb amputees suffering from chronic PAP. Keywords: post-amputation pain, phantom limb pain, neuromodulation, peripheral nerve stimulation, high-frequency nerve block There are currently 2.3 million lower limb amputees in the US, with approximat -Abstract Truncated-
clinical neurology